{"title":"Flow-cytometric Analysis of Reactive Oxygen Species in Blood Cells: A Potential Tool for Predicting Restenosis - Insights from a Cohort Study.","authors":"Rakesh Raman Patyar, Sazal Patyar, Yash Paul Sharma, Krishan Lal Khanduja","doi":"10.2174/011871529X341683241206073131","DOIUrl":"https://doi.org/10.2174/011871529X341683241206073131","url":null,"abstract":"<p><strong>Introduction: </strong>In-stent restenosis (ISR) is a recurrence of a blockage in a section of the coronary artery that has previously been treated with a stent. Molecular/biochemical pathways underlying ISR are not fully understood, but inflammation and reactive oxygen species (ROS) induced oxidative stress play a significant role in the pathogenesis of restenosis. As blood cells are highly sensitive to oxidative stress and blood is readily accessible compared to other tissues, the current study flow cytometrically investigated intracellular ROS and cytokine profile of blood cells as possible markers of restenosis. Flow cytometry is commonly used for detecting ROS and analyzing oxidative stress but so far, it has not been utilized for prediction of ISR. So, the aim of the study was to explore the potential of flow cytometric assessment of ROS levels in the blood cells as predictor of ISR.</p><p><strong>Methods: </strong>The study was carried out in a total of 60 patients who had previously undergone coronary artery stent implantation. They were categorized as Group I - Coronary stent implanted patients without restenosis (n=30) and Group II - Coronary stent implanted patients with restenosis (n=30). Sociodemographics, biochemical and angiographic characteristics were assessed. Intracellular ROS and cytokine estimation in blood cells was done by using flow cytometric analysis.</p><p><strong>Results: </strong>Flow cytometric measurements demonstrated a 1.3-fold increase in ROS levels in red blood cells (RBCs) and 2-fold increase in ROS levels in leucocytes in group II as compared to group I. Mean serum concentrations of pro-inflammatory cytokines: tumor necrosis factor-α (33.54 ± 6.48 vs. 20.10 ± 5.61, p <0.001***), interferon-gamma (21.76 ± 4.46 vs. 20.10 ± 5.61, p <0.001***), interleukin 6 (152.56 ± 30.67 vs. 113.95 ± 23.38, p <0.001***) were found to be higher in restenotic patients as compared to the non-restenotic patients. Correlation analysis showed that intracellular ROS levels of RBCs exhibited a significant positive correlation with late lumen loss in restenotic (r=0.71, p <0.01) as well as non-restenotic patients (r=0.59, p <0.01). Similarly, intracellular ROS levels of WBCs exhibited a significant positive correlation with late lumen loss in restenotic (r=0.72, p <0.01) as well as non-restenotic patients (r=0.61, p <0.01).</p><p><strong>Conclusion: </strong>This study highlights the role of increased levels of intracellular ROS in blood cells in the subsequent development of ISR, which can be detected flow cytometrically. The study suggests that intracellular ROS estimation in blood cells may serve as a potential marker for restenosis and their flow cytometric analysis may facilitate the prediction of ISR.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142840611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Repurposing of Empagliflozin as Cardioprotective Drug: An in-silico Approach.","authors":"Jyoti Yadav, Farogh Ahsan, Prabhudatta Panda, Tarique Mahmood, Shahzadi Bano, Arshiya Shamim, Pooja Mishra","doi":"10.2174/011871529X341930241206063315","DOIUrl":"https://doi.org/10.2174/011871529X341930241206063315","url":null,"abstract":"<p><strong>Background: </strong>Drug repurposing involves investigating new indications or uses for drugs that have already been approved for clinical use. Empagliflozin is a C-glycosyl compound characterized by the presence of a beta-glucosyl residue. It functions as a sodium-glucose co-transporter 2 inhibitor and is utilized to enhance glycemic control in adults diagnosed with type 2 diabetes mellitus. Additionally, it is indicated for the reduction of cardiovascular mortality risk in adult patients who have both type 2 diabetes mellitus and pre-existing cardiovascular disease.</p><p><strong>Objective: </strong>The study's objective revolves around exploring the repurposing potential of a novel SGLT2 inhibitor acting as an antidiabetic drug named Empagliflozin through computational methods, with a specific focus on its interaction with cardioprotective key target proteins.</p><p><strong>Methods: </strong>The study was performed by docking the empagliflozin with different target proteins (NHE1- CHP1, BIRC5, GLUT1, and XIAP) by using Autodock, and different values were recorded. The docked files were analysed by the BIOVIA Discovery Studio Visualizer. The in silico analysis conducted in this study examines the binding free energy values of Empagliflozin with key target proteins.</p><p><strong>Results: </strong>Results revealed that NHE1-CHP1 exhibits the lowest binding free energy, followed by BIRC5, GLUT1, and XIAP, with the highest value. This descending order of binding energies suggests varying degrees of effectiveness in binding molecules, with lower energies indicative of more potent biological activity. The analysis underscores the importance of intermolecular interactions, particularly hydrogen bond formations facilitated by oxygen, nitrogen, and carbonyl groups in compound structures. Notably, NHE1-CHP1 demonstrates superior binding interactions with Empagliflozin compared to the other target proteins, highlighting its potential as a cardioprotective agent.</p><p><strong>Conclusion: </strong>These findings offer valuable insights into the therapeutic possibilities of Empagliflozin in cardioprotection, indicating promising avenues for further research and development in this domain.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142839755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Soukaina Bougrine, Oumaima Abouyaala, Radia Elgui, Mohamed Yassine El Brouzi, Brahim Sow, Khadija Elmotia, Aboubaker El hessni, Abdelhalem Mesfioui, Moulay Laarbi Ouahidi
{"title":"Evaluation of the Hypoglycemic Activity of Methanolic Extract of Foeniculum Vulgare in Streptozotocin-induced Diabetic Wistar Rats.","authors":"Soukaina Bougrine, Oumaima Abouyaala, Radia Elgui, Mohamed Yassine El Brouzi, Brahim Sow, Khadija Elmotia, Aboubaker El hessni, Abdelhalem Mesfioui, Moulay Laarbi Ouahidi","doi":"10.2174/011871529X353419241203064748","DOIUrl":"10.2174/011871529X353419241203064748","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to assess the hypoglycemic effects of methanolic extract of Foeniculum vulgare in male Wistar rats that were diabetic due to streptozotocin.</p><p><strong>Methods: </strong>Experimental diabetes was initially induced in male Wistar rats by intravenous injection of streptozotocin (55 mg/kg). Subsequently, the rats received daily oral administration of the methanolic extract of Foeniculum vulgare (250 mg/kg) and the standard drug metformin (300 mg/kg) for 28 days. Furthermore, a tolerance test was carried out.</p><p><strong>Results: </strong>The study findings suggest that the diabetic rats in the untreated control group showed hyperglycemia and significant weight loss, as well as polydipsia, polyphagia, and polyuria. However, rats treated with methanolic extract of Foeniculum vulgare for 28 days showed a significant reduction in blood glucose levels and a marked improvement in body weight. Additionally, there was a notable decrease in the daily rate of food consumption and water intake and a significant reduction in serum glucose level, triglycerides, total cholesterol, creatinine, urea, AST, and ALT levels compared to the untreated diabetic control group. Histopathological examination revealed that after 28 days of treatment with 250 mg/kg of methanolic extract of the Foeniculum vulgare, the size of the islets of Langerhans in the pancreas tissue was decreased. Moreover, liver tissue demonstrated normalization with a normal central lobular structure, and kidney tissue showed normalization with a normal Bowman's capsule.</p><p><strong>Conclusion: </strong>These findings suggest that the methanolic extract of Foeniculum vulgare can potentially treat diabetes and should be evaluated further for drug development.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142796629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Environmental Factors, Occupational Hazards, and Seasonal Changes: Unveiling the Triggers of Atrial Fibrillation.","authors":"Adel Khalifa Sultan Hamad","doi":"10.2174/011871529X335166241203183331","DOIUrl":"https://doi.org/10.2174/011871529X335166241203183331","url":null,"abstract":"<p><strong>Introduction: </strong>Atrial Fibrillation (AF) is the most common cardiac arrhythmia in the world, with a lifetime risk of 26% for men and 23% for women. Atrial fibrillation is a prevalent cardiac arrhythmia that is more common with increasing age. Globally, around 33.5 million people are estimated to have AF, which is anticipated to rise as the population ages. Although effective therapeutic methods exist, they are costly for the healthcare system.</p><p><strong>Methods: </strong>The search was conducted across multiple databases, including Medline, PubMed, and Google Scholar, as well as through manual searches of recognized publications and their bibliographies. Identifying modifiable risk factors for AF and implementing appropriate preventative measures may significantly improve public health and reduce healthcare costs. The development of AF has been reported to be associated with various causes, including electrical and structural changes in the atrial tissue.</p><p><strong>Results: </strong>This article has reviewed how environmental factors, occupational hazards, and seasonal variability can affect AF. The incidence and prevalence of AF have been increasing, leading to a high lifetime risk for individuals. The available evidence indicates that seasonal variation, environmental factors, such as noise and air pollution, type of job, and altitude are all associated with an increased risk of developing AF. Although the exact mechanisms underlying these associations remain unclear, it is likely that a combination of factors, including changes in autonomic tone, inflammation, and oxidative stress, play a role.</p><p><strong>Conclusion: </strong>This review has highlighted the significance of assuming the role of environmental and occupational factors in the development of AF.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142796624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Novel Therapies for Nonalcoholic Steatohepatitis (NASH) and Cardiovascular Risk Reduction.","authors":"Tarun Biswas, Angelica Lehker, Debabrata Mukherjee","doi":"10.2174/011871529X345190241113103911","DOIUrl":"https://doi.org/10.2174/011871529X345190241113103911","url":null,"abstract":"<p><p>Nonalcoholic steatohepatitis (NASH) is a type of nonalcoholic fatty liver disease (NAFLD) characterized by hepatocyte injury and inflammation, in addition to only the presence of steatosis NAFLD. We review the existing data on available novel therapies for NASH and NAFLD and also discuss several therapies in development. We assessed therapies for NASH by searching the databases of PubMed, EMBASE, and Web of Science (SCI) from their inception dates until September 15, 2024. Search terms used were: nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, liver inflammation and hepatocyte injury.Until very recently, therapeutic lifestyle change was the primary modality of treatment for NASH, including modification of diet and physical activity. The FDA recently approved resmetirom using its expedited approval mechanism for NASH. There are also several pharmacotherapies in development for NASH which aim at weight loss, insulin sensitization and improvement in lipid levels, although some drugs may have multiple effects which are discussed. The availability of resmetirom offers patients with NASH an effective adjunctive therapy in addition to lifestyle changes. Several other novel therapies are also currently being tested and will add to our therapeutic armamentarium.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142677999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Olívia Moraes Ruberti, Heitor Moreno Junior, Bruno Rodrigues
{"title":"Exploring the Role of Prefrontal Cortex tDCS in Hypertension: A Mini-Review.","authors":"Olívia Moraes Ruberti, Heitor Moreno Junior, Bruno Rodrigues","doi":"10.2174/011871529X343701241113100959","DOIUrl":"https://doi.org/10.2174/011871529X343701241113100959","url":null,"abstract":"<p><p>Arterial Hypertension (HTN) is the leading cause of cardiovascular diseases, which, in turn, are the primary cause of mortality worldwide. The success rates in Blood Pressure (BP) control among the general population remain unacceptably low. HTN etiology is multifactorial, but ample evidence has shown an essential role of the Autonomic Nervous System (ANS) dysfunction in its physiopathology. Concurrently, studies have pointed to the promising effect of non-invasive cortical stimulation techniques, such as transcranial Direct Current Stimulation (tDCS), on modulating blood pressure and the ANS. tDCS involves the application of a direct low-intensity electric current between two electrodes (cathode and anode) placed on the scalp and skull over areas of interest in the cerebral cortex. The impacts of this technique on regulating BP levels and cardiovascular autonomic modulation have excellent potential to be explored in hypertension. This study aimed to review and discuss the existing evidence concerning the efficacy of tDCS in modulating BP and ANS, focusing on its potential as a therapeutic intervention for HTN. This narrative mini-review presents and discusses critical findings regarding using tDCS to modulate BP and the ANS. Data obtained from clinical and preclinical studies have been addressed in this work. The evidence gathered and discussed in this mini-review suggests the promising role of tDCS as a non-invasive intervention for HTN; however, the underlying mechanisms through which it exerts its effects remain poorly understood. More mechanistic studies must be carried out to draw definitive conclusions regarding the effectiveness and safety of tDCS as a treatment for HTN.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142677997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Comprehensive Review of Fear of Eating Behaviour in Individuals with Diabetes: Exploring Therapeutic Interventions for Diabulimia.","authors":"Ankita Wal, Pankaj Kumar Sahu, Pranay Wal, Kaminee Sahu, Manish Ramesh Bhise, Devendra Singh Lodhi","doi":"10.2174/011871529X326042241031060350","DOIUrl":"https://doi.org/10.2174/011871529X326042241031060350","url":null,"abstract":"<p><strong>Objective: </strong>This review aims to comprehensively analyse the fear of eating behaviour in individuals with diabetes, known as diabulimia or ED-DMT1. The emotional and psychological factors contributing to disordered eating behaviours, their impact on diabetes management, and potential consequences on physical health are explored. Various therapeutic interventions, including cognitive-behavioural therapy and psychological support, the role of nutrition education, individualized treatment plans support groups in managing fear of eating behaviour in diabetes are examined and discussed.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted to identify relevant studies, articles, and guidelines related to fear of eating behaviour in diabetes. The search included databases such as PubMed and Google Scholar using appropriate keywords.</p><p><strong>Results: </strong>The review highlights the emotional and psychological factors that contribute to the fear of eating behaviour in diabetes, including body image concerns, fear of weight gain, and disordered eating patterns. These behaviours can significantly impact diabetes management, leading to poor glycaemic control, increased risk of complications, and reduced overall well-being. Various therapeutic interventions, such as cognitive-behavioural therapy and mindfulness-based interventions, have shown promise in addressing the fear of eating behaviour.</p><p><strong>Conclusion: </strong>A multidisciplinary strategy combining healthcare specialists specializing in diabetes management, mental health, and nutrition is required for effective therapy of fear of eating behaviour in diabetes. Cognitive-behavioral therapy and mindfulness-based therapies, as well as psychological support, have shown potential in reducing the fear of eating habits. This analysis gives significant information for healthcare providers to help patients with diabetes who are afraid of eating and urges additional research on the topic.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142840610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Acute Myeloid Leukemia Presenting as Extensive Arterial and Venous Thrombosis: A Case Report.","authors":"Arjun Kachhwaha, Bibhant Shah, Kavya Ronanki, Prisla Maria Dalton, Uttam Kumar Nath","doi":"10.2174/011871529X334859241016114027","DOIUrl":"https://doi.org/10.2174/011871529X334859241016114027","url":null,"abstract":"<p><strong>Background: </strong>Thromboembolism with solid malignancies is a commonly associated feature, which is less common in hematological malignancies. Disseminated intravascular coagulation (DIC) causing thrombotic events is characteristically associated with certain hematological malignancies (e.g., acute promyelocytic leukemia (APL). Acute myeloid leukemia (AML) presenting as extensive thromboembolism is not a common clinical presentation. Anticoagulation in these subsets of patients remains a major challenge since patients often have thrombocytopenia and bleeding manifestations, requiring close monitoring.</p><p><strong>Case presentation: </strong>A 54-year-old male with a known case of ischemic heart disease on regular anti- platelet therapy presented with acute onset progressive shortness of breath with mild anemia. On further evaluation, the patient was diagnosed with bilateral pulmonary artery and venous thrombosis along with left complete renal and partial inferior vena cava (IVC) thrombosis. The patient was started safely on anticoagulant therapy with normal platelet counts. Later, peripheral smear and immunophenotyping by flow cytometry revealed the diagnosis of acute myeloid leukemia, and the patient started its treatment.</p><p><strong>Conclusion: </strong>Extensive arterial and venous thrombosis at presentation of acute myeloid leukemia is an uncommon finding and needs anticoagulation therapy along with the treatment of the underlying disease. Close monitoring of bleeding and maintaining an adequate platelet count is required, especially in hematological malignancies.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142559731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Inter-atrial Septum Stenting in Congenital Heart Disease Patient: A Case Series in Indonesia.","authors":"Radityo Prakoso, Yovi Kurniawati, Sisca Natalia Siagian, Aditya Agita Sembiring, Damba Dwisepto Aulia Sakti, Brian Mendel, Olfi Lelya, Oktavia Lilyasari","doi":"10.2174/011871529X320825240925073605","DOIUrl":"10.2174/011871529X320825240925073605","url":null,"abstract":"<p><strong>Background: </strong>Inter-atrial septum (IAS) stenting in duct-dependent congenital heart disease patient has shown to be an effective way to maintain inter-atrial blood flow, however it is still considered a high risk procedure and inter-atrial septum stenting remains a low-frequency procedure.</p><p><strong>Method: </strong>A single-center observational cohort study was carried out at the National Cardiovascular Center Harapan Kita (NCCHK) between April 2019 and April 2023. This study included duct-dependent congenital heart disease patients. The extracted data were baseline characteristics, clinical findings, complications, and outcomes of the patients.</p><p><strong>Result: </strong>Eleven patients with duct-dependent physiology were intervened with inter-atrial septum stenting. The patients were 4 females and 7 males with the median age of implantation being 150 days (range 11-703 days) and the median weight being 3.9 (range 2.8-9) kg, with 2 patients weighing less than 3 kg. The average stent diameter was 8.50 (2.03) mm with an average length of 24.45 (7.94) mm. Non-restrictive atrial flow was successfully achieved in 90.90% of the procedures, corresponding to 10 patients.</p><p><strong>Conclusion: </strong>Inter-atrial septum stenting in duct-dependent congenital heart disease patients produces reliable patency with a very good intra-procedural success rate.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":"163-171"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142483081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Toll-like Receptors: Therapeutic Potential in Life Threatening Diseases- Cardiac Disorders.","authors":"Sonia Singh","doi":"10.2174/011871529X348433240915133309","DOIUrl":"10.2174/011871529X348433240915133309","url":null,"abstract":"<p><p>Toll-like receptors (TLRs) belong to the innate immune system. TLRs identify and respond to invading pathogens by recognizing certain molecular patterns associated with the infections. TLRs are crucial for the host's defence against these diseases. TLRs are capable of detecting several endogenous chemicals through the recognition of damage-associated molecular patterns, which are generated in response to various harmful situations. Recent animal studies have shown that TLR signaling has a significant role in the development of serious heart diseases, such as ischemia myocardial damage, myocarditis, and septic cardiomyopathy, where inflammation of the heart muscle is a key factor. This manuscript examines the animal research findings on (1) TLRs, TLR ligands, and the signal transduction system, and (2) the significant involvement of TLR signaling in these crucial cardiac diseases.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":"125-133"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142334359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}